You have full text access to this OnlineOpen article

Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids

  1. H Zowall1,
  2. JA Cairns2,*,
  3. C Brewer3,
  4. DL Lamping2,
  5. WMW Gedroyc4,
  6. L Regan5

Article first published online: 7 MAR 2008

DOI: 10.1111/j.1471-0528.2007.01657.x

Issue

BJOG: An International Journal of Obstetrics & Gynaecology

BJOG: An International Journal of Obstetrics & Gynaecology

Volume 115, Issue 5, pages 653–662, April 2008

Additional Information

How to Cite

Zowall, H., Cairns, J., Brewer, C., Lamping, D., Gedroyc, W. and Regan, L. (2008), Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids. BJOG: An International Journal of Obstetrics & Gynaecology, 115: 653–662. doi: 10.1111/j.1471-0528.2007.01657.x

Author Information

  1. 1

    McGill University, Montreal, Quebec, Canada

  2. 2

    Health Services Research Unit, London School of Hygiene & Tropical Medicine, London, UK

  3. 3

    Zowall Consulting, Montreal, Quebec, Canada

  4. 4

    Departments of Magnetic Resonance Imaging

  5. 5

    Academic Obstetrics and Gynaecology, St Mary’s Hospital and Imperial College School of Medicine, London, UK

*Prof John Cairns, Public Health & Policy, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT. Tel 0207 927 2395. Email John.Cairns@lshtm.ac.uk

Publication History

  1. Issue published online: 7 MAR 2008
  2. Article first published online: 7 MAR 2008
  3. Accepted 6 December 2007.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (189K)

Keywords:

  • Cost-utility analysis;
  • focused ultrasound surgery;
  • uterine fibroids

Objective  To estimate the cost-effectiveness of a treatment strategy for symptomatic uterine fibroids, which starts with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) as compared with current practice comprising uterine artery embolisation, myomectomy and hysterectomy.

Design  Cost-utility analysis based on a Markov model.

Setting  National Health Service (NHS) Trusts in England and Wales.

Population  Women for whom surgical treatment for uterine fibroids is being considered.

Methods  The parameters of the Markov model of the treatment of uterine fibroids are drawn from a series of clinical studies of MRgFUS, and from the clinical effectiveness literature. Health-related quality of life is measured using the 6D. Costs are estimated from the perspective of the NHS. The impact of uncertainty is examined using deterministic and probabilistic sensitivity analysis.

Main outcome measures  Incremental cost-effectiveness measured by cost per quality-adjusted life-year (QALY) gained.

Results  The base-case results imply a cost saving and a small QALY gain per woman as a result of an MRgFUS treatment strategy. The cost per QALY gained is sensitive to cost of MRgFUS relative to other treatments, the age of the woman and the nonperfused volume relative to the total fibroids volume.

Conclusions  A treatment strategy for symptomatic uterine fibroids starting with MRgFUS is likely to be cost-effective.

View Full Article (HTML) Get PDF (189K)